Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19

DiNicolantonio et al., Open Heart, doi:10.1136/openhrt-2020-001350
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
Review suggesting that ivermectin may be useful for late stage COVID-19. Authors note that ivermectin, in doses at or modestly above the standard clinical dose, may have important clinical potential for managing disorders associated with life-threatening respiratory distress and cytokine storm, such as advanced COVID-19.
Reviews covering ivermectin for COVID-19 include1-38.
DiNicolantonio et al., 6 Sep 2020, peer-reviewed, 3 authors.
This PaperIvermectinAll
Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19
Dr James J Dinicolantonio, Jorge Barroso, Mark Mccarty
Open Heart, doi:10.1136/openhrt-2020-001350
Author name Jorge Barroso has been corrected to Jorge Barroso-Aranda.
References
Andersson, Ottestad, Tracey, Extracellular HMGB1: a therapeutic target in severe pulmonary inflammation including COVID-19?, Mol Med, doi:10.1186/s10020-020-00172-4
Caly, Druce, Catton, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Capellini, Venditti, Barton, Phylogeny and metabolic scaling in mammals, Ecology, doi:10.1890/09-0817.1
Ci, Li, Yu, Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, doi:10.1111/j.1472-8206.2009.00684.x
Gorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management, medRxiv
Rajter, Sm, Fatteh, Vogel, Icon (ivermectin Ni COvid nineteen) study: use of ivermectin is associated with lower mortality in hospitalized patients with COVID19, medRxiv
Schmith, Zhou, Lohmer, The Approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, doi:10.1002/cpt.1889
Ventre, Rozières, Lenief, Topical ivermectin improves allergic skin inflammation, Allergy, doi:10.1111/all.13118
Yan, Ci, Chen, Anti-Inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8
Zhang, Song, Ci, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8
Zhang, Song, Xiong, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol, doi:10.1016/j.intimp.2008.12.016
{ 'indexed': {'date-parts': [[2024, 5, 14]], 'date-time': '2024-05-14T18:01:48Z', 'timestamp': 1715709708614}, 'reference-count': 11, 'publisher': 'BMJ', 'issue': '2', 'license': [ { 'start': { 'date-parts': [[2020, 9, 4]], 'date-time': '2020-09-04T00:00:00Z', 'timestamp': 1599177600000}, 'content-version': 'unspecified', 'delay-in-days': 3, 'URL': 'http://creativecommons.org/licenses/by-nc/4.0/'}], 'content-domain': {'domain': ['bmj.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 9]]}, 'DOI': '10.1136/openhrt-2020-001350', 'type': 'journal-article', 'created': {'date-parts': [[2020, 9, 7]], 'date-time': '2020-09-07T07:35:23Z', 'timestamp': 1599464123000}, 'page': 'e001350', 'update-policy': 'http://dx.doi.org/10.1136/crossmarkpolicy', 'source': 'Crossref', 'is-referenced-by-count': 26, 'title': 'Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19', 'prefix': '10.1136', 'volume': '7', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7888-1528', 'authenticated-orcid': False, 'given': 'James J', 'family': 'DiNicolantonio', 'sequence': 'first', 'affiliation': []}, {'given': 'Jorge', 'family': 'Barroso', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mark', 'family': 'McCarty', 'sequence': 'additional', 'affiliation': []}], 'member': '239', 'published-online': {'date-parts': [[2020, 9, 6]]}, 'reference': [ { 'key': '2020090700350916000_7.2.e001350.1', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '2020090700350916000_7.2.e001350.2', 'doi-asserted-by': 'crossref', 'DOI': '10.1002/cpt.1889', 'article-title': 'The Approved dose of ivermectin alone is not the ideal dose for the ' 'treatment of COVID-19', 'author': 'Schmith', 'year': '2020', 'journal-title': 'Clin Pharmacol Ther'}, { 'key': '2020090700350916000_7.2.e001350.3', 'doi-asserted-by': 'publisher', 'DOI': '10.1007/s00011-008-8007-8'}, { 'key': '2020090700350916000_7.2.e001350.4', 'doi-asserted-by': 'crossref', 'first-page': '354', 'DOI': '10.1016/j.intimp.2008.12.016', 'article-title': 'Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 ' 'production in LPS-stimulated RAW 264.7 macrophages', 'volume': '9', 'author': 'Zhang', 'year': '2009', 'journal-title': 'Int Immunopharmacol'}, { 'key': '2020090700350916000_7.2.e001350.5', 'doi-asserted-by': 'publisher', 'DOI': '10.1890/09-0817.1'}, { 'key': '2020090700350916000_7.2.e001350.6', 'doi-asserted-by': 'crossref', 'first-page': '449', 'DOI': '10.1111/j.1472-8206.2009.00684.x', 'article-title': 'Avermectin exerts anti-inflammatory effect by downregulating the ' 'nuclear transcription factor kappa-B and mitogen-activated protein ' 'kinase activation pathway', 'volume': '23', 'author': 'Ci', 'year': '2009', 'journal-title': 'Fundam Clin Pharmacol'}, { 'key': '2020090700350916000_7.2.e001350.7', 'doi-asserted-by': 'crossref', 'first-page': '589', 'DOI': '10.1007/s00011-011-0307-8', 'article-title': 'Anti-Inflammatory effects of ivermectin in mouse model of allergic ' 'asthma', 'volume': '60', 'author': 'Yan', 'year': '2011', 'journal-title': 'Inflamm Res'}, { 'key': '2020090700350916000_7.2.e001350.8', 'doi-asserted-by': 'crossref', 'first-page': '1212', 'DOI': '10.1111/all.13118', 'article-title': 'Topical ivermectin improves allergic skin inflammation', 'volume': '72', 'author': 'Ventre', 'year': '2017', 'journal-title': 'Allergy'}, { 'key': '2020090700350916000_7.2.e001350.9', 'doi-asserted-by': 'crossref', 'first-page': '42', 'DOI': '10.1186/s10020-020-00172-4', 'article-title': 'Extracellular HMGB1: a therapeutic target in severe pulmonary ' 'inflammation including COVID-19?', 'volume': '26', 'author': 'Andersson', 'year': '2020', 'journal-title': 'Mol Med'}, { 'key': '2020090700350916000_7.2.e001350.10', 'doi-asserted-by': 'crossref', 'unstructured': 'Rajter.J.C. SM , Fatteh N , Vogel F , et al . Icon (ivermectin Ni COvid ' 'nineteen) study: use of ivermectin is associated with lower mortality in ' 'hospitalized patients with COVID19. medRxiv 2020.', 'DOI': '10.1101/2020.06.06.20124461'}, { 'key': '2020090700350916000_7.2.e001350.11', 'doi-asserted-by': 'crossref', 'unstructured': 'Gorial FI , Mashhadani S , Sayaly HM , et al . Effectiveness of ' 'ivermectin as add-on therapy in COVID-19 management (pilot trial). ' 'medRxiv 2020.', 'DOI': '10.1101/2020.07.07.20145979'}], 'container-title': 'Open Heart', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1136/openhrt-2020-001350', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2020, 9, 26]], 'date-time': '2020-09-26T10:50:00Z', 'timestamp': 1601117400000}, 'score': 1, 'resource': {'primary': {'URL': 'https://openheart.bmj.com/lookup/doi/10.1136/openhrt-2020-001350'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 9]]}, 'references-count': 11, 'journal-issue': { 'issue': '2', 'published-online': {'date-parts': [[2020, 9, 6]]}, 'published-print': {'date-parts': [[2020, 9]]}}, 'alternative-id': ['10.1136/openhrt-2020-001350'], 'URL': 'http://dx.doi.org/10.1136/openhrt-2020-001350', 'relation': {}, 'ISSN': ['2053-3624'], 'subject': [], 'container-title-short': 'Open Heart', 'published': {'date-parts': [[2020, 9]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit